PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schrom, E.* ; Huber, M.* ; Aneja, M.K.* ; Dohmen, C.* ; Emrich, D.* ; Geiger, J.* ; Hasenpusch, G.* ; Herrmann-Janson, A.* ; Kretzschmann, V.* ; Mykhailyk, O.* ; Pasewald, T.* ; Oak, P. ; Hilgendorff, A. ; Wohlleber, D.* ; Hoymann, H.* ; Schaudien, D.* ; Plank, C.* ; Rudolph, C.* ; Kubisch-Dohmen, R.*

Translation of angiotensin-converting enzyme 2 upon liver- and lung-targeted delivery of optimized chemically modified mRNA.

Mol. Ther. Nucleic Acids 7, 350-365 (2017)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Changes in lifestyle and environmental conditions give rise to an increasing prevalence of liver and lung fibrosis, and both have a poor prognosis. Promising results have been reported for recombinant angiotensin-converting enzyme 2 ( ACE2) protein administration in experimental liver and lung fibrosis. However, the full potential of ACE2 may be achieved by localized translation of a membrane-anchored form. For this purpose, we advanced the latest RNA technology for liver-and lung-targeted ACE2 translation. We demonstrated in vitro that transfection with ACE2 chemically modified messenger RNA (cmRNA) leads to robust translation of fully matured, membrane-anchored ACE2 protein. In a second step, we designed eight modified ACE2 cmRNA sequences and identified a lead sequence for in vivo application. Finally, formulation of this ACE2 cmRNA in tailor-made lipidoid nanoparticles and in lipid nanoparticles led to liver-and lung-targeted translation of significant amounts of ACE2 protein, respectively. In summary, we provide evidence that RNA transcript therapy (RTT) is a promising approach for ACE2-based treatment of liver and lung fibrosis to be tested in fibrotic disease models.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.392
1.160
36
50
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ace2 ; Rna Therapy ; Cmrna ; Mrna Delivery ; Modified Mrna; Idiopathic Pulmonary-fibrosis; Alveolar Epithelial-cells; Hepatic Stellate Cells; Induced Apoptosis; Receptor; Expression; Therapeutics; Ace2; Mice; Angiotensin-converting-enzyme-2
Sprache
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 2162-2531
e-ISSN 2162-2531
Zeitschrift Molecular therapy - Nucleic Acids
Quellenangaben Band: 7, Heft: , Seiten: 350-365 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort New York, NY
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30503 - Chronic Diseases of the Lung and Allergies
30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-508700-004
G-552100-001
DOI 10.1016/j.omtn.2017.04.006
WOS ID WOS:000401233700033
Scopus ID 85020815428
PubMed ID 28624211
Erfassungsdatum 2017-06-21
[➜Korrektur melden]